Helicobacter pyloriによる胃病理における悪循環誘導:胃癌発症への示唆
Amiratabak Rajaei1, Pooya Mahdavi2, Rojan Chimehrad1
1Department of Molecular Biosciences, University of South Florida, Tampa, FL, USA.
Archives of microbiology
|January 12, 2026
まとめ
Helicobacter pylori感染はBRCAness状態を引き起こし、DNA修復を阻害してゲノム不安定性を引き起こす。これは免疫かく乱とともに胃癌の発症を促進し、潜在的な介入標的を提供する。
科学分野:
- 微生物学;腫瘍学;分子生物学
背景:
- Helicobacter pyloriは、癌を含む胃疾患の主要な原因である。; CagAやVacAなどの病原因子がH. pyloriの病因に寄与する。; H. pylori関連胃癌を駆動する統合メカニズムは完全には理解されていない。
研究 の 目的:
- H. pyloriの病原因子が胃癌発症に果たす協調的な役割をレビューする。; H. pyloriがDNA修復と宿主免疫応答をどのように破壊するかを解明する。; H. pylori関連胃癌を予防するための潜在的な介入点を特定する。
主な方法:
- H. pylori病原因子に関するエビデンスを統合した文献レビュー。; DNA損傷および修復障害の分子メカニズムの解析。; 宿主免疫シグナル伝達経路に対するH. pyloriの影響の検討。
主要な成果:
- H. pylori感染は一過性のBRCAness状態を誘導し、相同組換え欠損とゲノム不安定性をもたらす。; CagA非依存性経路と活性酸素種がDNA二本鎖切断に寄与する。; 感染は腫瘍抑制経路(p53)と免疫シグナル伝達(NF-κB、JAK/STAT)を調節不全にし、免疫回避を促進する。
結論:
- H. pylori病原因子、DNA損傷、免疫調節の協調作用が胃癌発症を駆動する。; これらの統合メカニズムの理解は、治療介入の潜在的な標的を明らかにする。; H. pylori感染とその関連経路を破壊することは、胃癌のリスクを低減する可能性がある。
関連する概念動画
Gastritis-II: Pathophysiology
1.2K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.2K
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
1.1K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.1K
Peptic Ulcer Disease I: Introduction
725
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
725
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.1K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.1K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.1K
Peptic Ulcer Disease II: Pathophysiology
1.9K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.9K


